Healthcare provider profile · identity verified

David Benjamin Kuhns, MD

Family Practice · MONTOURSVILLE, PA · NPI 1922215771

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	311	90
Lisinopril	Lisinopril	233	54
Levothyroxine Sodium	Levothyroxine Sodium	203	57
Amlodipine Besylate	Amlodipine Besylate	197	57
Duloxetine Hcl	Duloxetine Hcl	183	34
Tamsulosin Hcl	Tamsulosin Hcl	175	47
Hydrochlorothiazide	Hydrochlorothiazide	153	37
Losartan Potassium	Losartan Potassium	148	39
Omeprazole	Omeprazole	147	39
Pravastatin Sodium	Pravastatin Sodium	146	32
Pantoprazole Sodium	Pantoprazole Sodium	126	34
Metformin Hcl	Metformin Hcl	112	36
Furosemide	Furosemide	101	28
Gabapentin	Gabapentin	90	27
Rosuvastatin Calcium	Rosuvastatin Calcium	84	28
Eliquis	Apixaban	81	20
Meloxicam	Meloxicam	81	24
Ozempic	Semaglutide	81	13
Jardiance	Empagliflozin	80	18
Albuterol Sulfate Hfa	Albuterol Sulfate	78	35
Metoprolol Succinate	Metoprolol Succinate	77	28
Potassium Chloride	Potassium Chloride	74	21
Simvastatin	Simvastatin	72	23
Warfarin Sodium	Warfarin Sodium	72	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	72	11
Famotidine	Famotidine	65	18
Sertraline Hcl	Sertraline Hcl	65	20
Tramadol Hcl	Tramadol Hcl	57	15
Escitalopram Oxalate	Escitalopram Oxalate	54	15
Metformin Hcl Er	Metformin Hcl	53	17
Prednisone	Prednisone	53	36
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	51	42
Allopurinol	Allopurinol	50	13
Glimepiride	Glimepiride	50	14
Glipizide Er	Glipizide	44	suppressed
Carvedilol	Carvedilol	43	13
Montelukast Sodium	Montelukast Sodium	43	14
Metoprolol Tartrate	Metoprolol Tartrate	42	suppressed
Clonazepam	Clonazepam	41	suppressed
Fluticasone Propionate	Fluticasone Propionate	41	11
Finasteride	Finasteride	40	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	12
Fenofibrate	Fenofibrate	38	suppressed
Trazodone Hcl	Trazodone Hcl	37	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	11
Spironolactone	Spironolactone	36	suppressed
Alprazolam	Alprazolam	35	suppressed
Atenolol	Atenolol	35	suppressed
Alendronate Sodium	Alendronate Sodium	34	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Irbesartan	Irbesartan	29	suppressed
Farxiga	Dapagliflozin Propanediol	28	suppressed
Pregabalin	Pregabalin	27	suppressed
Baclofen	Baclofen	26	suppressed
Ezetimibe	Ezetimibe	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	11
Lorazepam	Lorazepam	25	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Tresiba Flextouch U-100	Insulin Degludec	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Terazosin Hcl	Terazosin Hcl	23	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Levetiracetam	Levetiracetam	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Testosterone Cypionate	Testosterone Cypionate	20	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	17
Tresiba Flextouch U-200	Insulin Degludec	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Larin	Norethindrone Ac/Eth Estradiol	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	13
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Temazepam	Temazepam	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	14	suppressed
Colestipol Hcl	Colestipol Hcl	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Dextroamphetamine Sulfate	Dextroamphetamine Sulfate	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Klor-Con M20	Potassium Chloride	13	suppressed
Valsartan	Valsartan	13	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	12	suppressed
Dexlansoprazole Dr	Dexlansoprazole	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Risperidone	Risperidone	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed
Tadalafil	Tadalafil	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error